Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Decreased by New York State Common Retirement Fund

New York State Common Retirement Fund reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 130,540 shares of the biopharmaceutical company's stock after selling 6,846 shares during the quarter. New York State Common Retirement Fund owned 0.12% of Regeneron Pharmaceuticals worth $82,792,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in REGN. Capital International Investors raised its position in shares of Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares in the last quarter. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $802,036,000. GAMMA Investing LLC raised its position in shares of Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after acquiring an additional 810,144 shares in the last quarter. Finally, Loomis Sayles & Co. L P raised its position in shares of Regeneron Pharmaceuticals by 33.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock valued at $1,122,168,000 after acquiring an additional 393,997 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. The Goldman Sachs Group dropped their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Robert W. Baird dropped their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. JPMorgan Chase & Co. dropped their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. Cantor Fitzgerald started coverage on Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price target on the stock. Finally, Citigroup lowered their price target on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a report on Monday, June 2nd. One analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $823.54.

Regeneron Pharmaceuticals Trading Down 2.5%

Shares of NASDAQ:REGN traded down $14.05 during midday trading on Tuesday, reaching $556.54. The company had a trading volume of 209,891 shares, compared to its average volume of 913,921. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The firm has a market cap of $60.09 billion, a price-to-earnings ratio of 14.16, a price-to-earnings-growth ratio of 2.11 and a beta of 0.33. The company has a fifty day simple moving average of $544.56 and a two-hundred day simple moving average of $618.18.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the previous year, the business posted $9.55 earnings per share. The company's revenue was down 3.7% compared to the same quarter last year. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.63%. Regeneron Pharmaceuticals's payout ratio is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.